Across TCGA pan-cancer cohorts, RIMBP3C RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated RIMBP3C data layer compared with 2 for mutation status.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RIMBP3C RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RIMBP3C expression acts as an unfavorable survival marker, although some lineages such as PAAD and THCA show a favorable association.
LIHC, PAAD, and THCA are the cancer types where RIMBP3C RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.